calendar
121 catalysts · 3,921 phase readout · 2,141 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 108 grant
121 catalysts · 3,921 phase readout · 2,141 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 108 grant
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL
Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Angio Packs (AMS6908E and AMS6908F)
Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration
This page contains notices of advisory committee meetings. Refer to the individual meeting link below for more information on the anticipated format of each meeting. For previous years' advisory committee calendars, see the FDA Archive.
Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL
Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL
Sponsor: ACCORD HLTHCARE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: CAPSULE. Route: ORAL
Vanilla Bourbon Trail Mix
Therapy area: Ophthalmology. Indication: Choroidal Neovascularization
Therapy area: Genetic Disorders. Indication: Duchenne Muscular Dystrophy
Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion
Therapy area: Ophthalmology. Indication: Diabetic Retinopathy
Therapy area: Ophthalmology. Indication: Diabetic Macular Edema
Sponsor: NOVARTIS. Form: TABLET. Route: ORAL